FOLD
Price
$7.49
Change
-$0.12 (-1.58%)
Updated
Aug 25, 04:59 PM (EDT)
Capitalization
2.31B
72 days until earnings call
PVLA
Price
$50.10
Change
-$3.32 (-6.21%)
Updated
Aug 25, 04:59 PM (EDT)
Capitalization
554.42M
Interact to see
Advertisement

FOLD vs PVLA

Header iconFOLD vs PVLA Comparison
Open Charts FOLD vs PVLABanner chart's image
Amicus Therapeutics
Price$7.49
Change-$0.12 (-1.58%)
Volume$107.97K
Capitalization2.31B
Palvella Therapeutics
Price$50.10
Change-$3.32 (-6.21%)
Volume$2.1K
Capitalization554.42M
FOLD vs PVLA Comparison Chart in %
Loading...
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PVLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FOLD vs. PVLA commentary
Aug 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FOLD is a Buy and PVLA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 26, 2025
Stock price -- (FOLD: $7.61 vs. PVLA: $53.42)
Brand notoriety: FOLD and PVLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FOLD: 90% vs. PVLA: 99%
Market capitalization -- FOLD: $2.31B vs. PVLA: $554.42M
FOLD [@Biotechnology] is valued at $2.31B. PVLA’s [@Biotechnology] market capitalization is $554.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $99.72B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FOLD’s FA Score shows that 0 FA rating(s) are green whilePVLA’s FA Score has 1 green FA rating(s).

  • FOLD’s FA Score: 0 green, 5 red.
  • PVLA’s FA Score: 1 green, 4 red.
According to our system of comparison, PVLA is a better buy in the long-term than FOLD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FOLD’s TA Score shows that 5 TA indicator(s) are bullish while PVLA’s TA Score has 3 bullish TA indicator(s).

  • FOLD’s TA Score: 5 bullish, 4 bearish.
  • PVLA’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, FOLD is a better buy in the short-term than PVLA.

Price Growth

FOLD (@Biotechnology) experienced а +2.84% price change this week, while PVLA (@Biotechnology) price change was +12.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.14%. For the same industry, the average monthly price growth was +18.77%, and the average quarterly price growth was +29.32%.

Reported Earning Dates

FOLD is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+2.14% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FOLD($2.31B) has a higher market cap than PVLA($554M). PVLA YTD gains are higher at: 345.167 vs. FOLD (-19.214). FOLD has higher annual earnings (EBITDA): 33.1M vs. PVLA (-23.27M). FOLD has more cash in the bank: 231M vs. PVLA (70.4M). FOLD has higher revenues than PVLA: FOLD (571M) vs PVLA (0).
FOLDPVLAFOLD / PVLA
Capitalization2.31B554M416%
EBITDA33.1M-23.27M-142%
Gain YTD-19.214345.167-6%
P/E RatioN/A14.22-
Revenue571M0-
Total Cash231M70.4M328%
Total Debt443MN/A-
FUNDAMENTALS RATINGS
FOLD vs PVLA: Fundamental Ratings
FOLD
PVLA
OUTLOOK RATING
1..100
3538
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
5035
P/E GROWTH RATING
1..100
10012
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FOLD's Valuation (63) in the Biotechnology industry is in the same range as PVLA (70) in the null industry. This means that FOLD’s stock grew similarly to PVLA’s over the last 12 months.

FOLD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PVLA (100) in the null industry. This means that FOLD’s stock grew similarly to PVLA’s over the last 12 months.

FOLD's SMR Rating (95) in the Biotechnology industry is in the same range as PVLA (97) in the null industry. This means that FOLD’s stock grew similarly to PVLA’s over the last 12 months.

PVLA's Price Growth Rating (35) in the null industry is in the same range as FOLD (50) in the Biotechnology industry. This means that PVLA’s stock grew similarly to FOLD’s over the last 12 months.

PVLA's P/E Growth Rating (12) in the null industry is significantly better than the same rating for FOLD (100) in the Biotechnology industry. This means that PVLA’s stock grew significantly faster than FOLD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FOLDPVLA
RSI
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
84%
Momentum
ODDS (%)
Bullish Trend 4 days ago
79%
N/A
MACD
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
70%
Bullish Trend 4 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 4 days ago
70%
Bullish Trend 4 days ago
85%
Declines
ODDS (%)
Bearish Trend 15 days ago
77%
Bearish Trend 25 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
78%
Bullish Trend 4 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
FOLD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PVLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSCVX27.241.01
+3.85%
Nuveen Small Cap Value C
KBIWX12.310.26
+2.16%
KBI Global Investors Aquarius Instl
TIOHX16.880.29
+1.75%
Nuveen International Opps I
PCCOX64.350.96
+1.51%
T. Rowe Price U.S. Equity Research I
HNDRX82.420.58
+0.71%
Horizon Defined Risk Investor

FOLD and

Correlation & Price change

A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FOLD
1D Price
Change %
FOLD100%
+0.13%
VCYT - FOLD
43%
Loosely correlated
+5.33%
ATXS - FOLD
42%
Loosely correlated
+6.93%
IRON - FOLD
41%
Loosely correlated
+1.00%
ROIV - FOLD
40%
Loosely correlated
+0.93%
XENE - FOLD
40%
Loosely correlated
+1.73%
More

PVLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PVLA has been loosely correlated with DRMA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if PVLA jumps, then DRMA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PVLA
1D Price
Change %
PVLA100%
+4.11%
DRMA - PVLA
42%
Loosely correlated
+2.81%
OCUL - PVLA
34%
Loosely correlated
+1.40%
RGNX - PVLA
33%
Poorly correlated
+11.10%
FOLD - PVLA
32%
Poorly correlated
+0.13%
ERAS - PVLA
32%
Poorly correlated
+6.67%
More